press releases

Phase 3 pivotal trial will study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for brain metastases from non-small cell lung cancer Phase 3 pivotal trial will study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for brain metastases from non-small cell lung cancer… Read More

Phase 3 pivotal trial will study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for brain metastases from non-small cell lung cancer Phase 3 pivotal trial will study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for brain metastases from non-small cell lung cancer… Read More

The first cohort testing TTFields plus gemcitabine suggests improved survival and response rate compared to a historical control of gemcitabine alone The first cohort testing TTFields plus gemcitabine suggests improved survival and response rate compared to a historical control of gemcitabine alone May 23, 2016 07:30… Read More

The first cohort testing TTFields plus gemcitabine suggests improved survival and response rate compared to a historical control of gemcitabine alone The first cohort testing TTFields plus gemcitabine suggests improved survival and response rate compared to a historical control of gemcitabine alone May 23, 2016 07:30… Read More

The first cohort testing TTFields plus gemcitabine suggests improved survival and response rate compared to a historical control of gemcitabine alone The first cohort testing TTFields plus gemcitabine suggests improved survival and response rate compared to a historical control of gemcitabine alone May 23, 2016 07:30… Read More

Trial tests safety and potential synergy between a taxane and TTFields in the treatment of recurrent ovarian cancer Trial tests safety and potential synergy between a taxane and TTFields in the treatment of recurrent ovarian cancer May 19, 2016 04:30 PM Eastern Daylight Time ST. HELIER,… Read More

Trial tests safety and potential synergy between a taxane and TTFields in the treatment of recurrent ovarian cancer Trial tests safety and potential synergy between a taxane and TTFields in the treatment of recurrent ovarian cancer May 19, 2016 04:30 PM Eastern Daylight Time ST. HELIER,… Read More

Trial tests safety and potential synergy between a taxane and TTFields in the treatment of recurrent ovarian cancer Trial tests safety and potential synergy between a taxane and TTFields in the treatment of recurrent ovarian cancer May 19, 2016 04:30 PM Eastern Daylight Time ST. HELIER,… Read More

Median overall survival exceeded 15 months in patients with locally advanced pancreatic cancer treated with TTFields therapy combined with gemcitabine Median overall survival exceeded 15 months in patients with locally advanced pancreatic cancer treated with TTFields therapy combined with gemcitabine Metastatic pancreatic cancer patients… Read More